SCFA, especially butyrate, as HDAC inhibitors, play a beneficial role in sustained low-grade inflammation in obesity and especially in balancing pro-inflammatory and anti-inflammatory immune responses, which has great research significance for the treatment of obesity. Here, HDAC9 is linked to obesity disorder.